Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2226419 | 1.00 | ALDH1A1 (0.44) | ALDH1A1PDE4ATDP1LMNAUSP2 | |
| SCHEMBL2123185 | 0.99 | ALDH1A1 (0.43) | ALDH1A1PDE4ATDP1LMNAUSP2 | |
| Water SCHEMBL12006104 | 0.99 | ALDH1A1 (0.43) | ALDH1A1PDE4ATDP1LMNAUSP2 | |
| SCHEMBL21807343 | 0.99 | ALDH1A1 (0.43) | ALDH1A1PDE4ATDP1LMNAUSP2 | |
| SCHEMBL6747136 | 0.99 | ALDH1A1 (0.43) | ALDH1A1PDE4ATDP1LMNAUSP2 | |
| SCHEMBL27671942 | 0.99 | ALDH1A1 (0.43) | ALDH1A1PDE4ATDP1LMNAUSP2 | |
| SCHEMBL2123797 | 0.99 | ALDH1A1 (0.43) | ALDH1A1PDE4ATDP1LMNAUSP2 | |
| Ammonia Solution, Strong SCHEMBL2472996 | 0.99 | ALDH1A1 (0.43) | ALDH1A1PDE4ATDP1LMNAUSP2 | |
| SCHEMBL28436426 | 0.94 | ALDH1A1 (0.47) | ALDH1A1PDE4ALMNAUSP2SLCO1B1 | |
| SCHEMBL5566462 | 0.84 | ALDH1A1 (0.43) | ALDH1A1PDE4ATDP1LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106631779-B | Polyol esters and their use in processing halogenated vinyl polymers | 济南金昌树新材料科技有限公司 | 2020-07-14 | — | — | CN | claimed |
| CN-106631779-A | Polyol ester and application of same to processing of halogenated vinyl polymer | 山东金昌树新材料科技有限公司 | 2017-05-10 | — | — | CN | claimed |
| US-10729659-B2 | Nanogel-mediated drug delivery | THE CLEVELAND CLINIC FOUNDATION (US) | 2020-08-04 | — | — | US | disclosed |
| CN-106631779-B | Polyol esters and their use in processing halogenated vinyl polymers | 济南金昌树新材料科技有限公司 | 2020-07-14 | — | — | CN | disclosed |
| US-20190091161-A1 | Nanogel-Mediated Drug Delivery | THE CLEVELAND CLINIC FOUNDATION | 2019-03-28 | — | — | US | disclosed |
| US-10206885-B2 | Nanogel-mediated drug delivery | THE CLEVELAND CLINIC FOUNDATION (US) | 2019-02-19 | — | — | US | disclosed |
| CN-106667937-A | Lycium ruthenicum polysaccharide chewable tablet | 河北省农林科学院经济作物研究所 | 2017-05-17 | — | — | CN | disclosed |
| CN-106631779-A | Polyol ester and application of same to processing of halogenated vinyl polymer | 山东金昌树新材料科技有限公司 | 2017-05-10 | — | — | CN | disclosed |
| US-20160324930-A1 | SYSTEMS AND METHODS FOR THERAPY OF KIDNEY DISEASE AND/OR HEART FAILURE USING CHIMERIC NATRIURETIC PEPTIDES | CAPRICOR THERAPEUTICS INC (US) | 2016-11-10 | — | — | US | disclosed |
| US-20160250152-A1 | Nanogel-Mediated Drug Delivery | THE CLEVELAND CLINIC FOUNDATION | 2016-09-01 | — | — | US | disclosed |
| WO-2016118921-A1 | COMPOSITIONS AND METHODS FOR TREATING PSORIATIC ARTHRITIS | ABBVIE, INC. (US) | 2016-07-28 | — | — | WO | disclosed |
| US-20120220528-A1 | SYSTEMS AND METHODS FOR THERAPY OF KIDNEY DISEASE AND/OR HEART FAILURE USING CHIMERIC NATRIURETIC PEPTIDES | MEDTRONIC, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| EP-2427061-A2 | GALLIUM FORMULATION FOR THE TREATMENT AND PREVENTION OF INFECTIOUS DISEASES | Aridis Pharmaceuticals (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011005354-A9 | GALLIUM FORMULATION FOR THE TREATMENT AND PREVENTION OF INFECTIOUS DISEASES | ARIDIS PHARMACEUTICALS (US) | 2011-03-03 | — | — | WO | disclosed |
| WO-2011005354-A2 | GALLIUM FORMULATION FOR THE TREATMENT AND PREVENTION OF INFECTIOUS DISEASES | ARIDIS PHARMACEUTICALS (US) | 2011-01-13 | — | — | WO | disclosed |
| CN-1835754-A | Stable freeze-dried preparation of tetrodotoxin for medical use | FENGYE PHARMACEUTICAL CO LTD N (CN) | 2006-09-20 | — | — | CN | disclosed |
| EP-1169053-A1 | PULMONARY ADMINISTRATION OF DRY POWDER FORMULATIONS FOR TREATING INFERTILITY | Inhale Therapeutic Systems, Inc. (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061178-A1 | PULMONARY ADMINISTRATION OF DRY POWDER FORMULATIONS FOR TREATING INFERTILITY | INHALE THERAPEUTICS SYSTEMS, INC. (US) | 2000-10-19 | — | — | WO | disclosed |
| US-5215743-A | Mixed with stabilizers, buffers and solute; mannitol, dextran, citrate buffer, glycine | CHIRON CORPORATION | 1993-06-01 | — | — | US | disclosed |
| US-4412986-A | COPRECIPITATED WITH POLYVINYLPYRROLIDONE OR A CELLULOSE ETHER | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1983-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220528-A1 | SYSTEMS AND METHODS FOR THERAPY OF KIDNEY DISEASE AND/OR HEART FAILURE USING CHIMERIC NATRIURETIC PEPTIDES | NPPA, NPR1, NPR3 | ALDH1A1 4452/4885PDE4A 1085/4885TDP1 4505/4885 |
| US-20160324930-A1 | SYSTEMS AND METHODS FOR THERAPY OF KIDNEY DISEASE AND/OR HEART FAILURE USING CHIMERIC NATRIURETIC PEPTIDES | NPPA, NPR1, NPR3 | ALDH1A1 4452/4885PDE4A 1085/4885TDP1 4505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.